Top Ten Common Prejudices About Polyethylene Naphthalate Market.
The Asia-Pacific (APAC) market for companion diagnostics (CDx) is predicted to develop at the quickest rate, since CDx will be crucial in reducing APAC's high cancer burden and promoting effective oncology care.
Though single biomarker CDx has had relatively easy market access, next-generation sequencing-based CDx is facing reimbursement issues in APAC nations, which cannot afford high costs without local demonstration of benefits.
Companies should build appropriate alliances to demonstrate that using CDx and tailored therapies decreases total healthcare costs to unleash the value of the CDx market in APAC.
With 60 percent of the world's population, the Asia-Pacific (APAC) region bears a large proportion of the worldwide cancer burden. Because APAC has a higher prevalence of some cancers and different Asian patient genotypes, diagnosis and treatment should be adapted to the APAC population. As a result, industry players have the opportunity to develop and expand the clinical usage of precision oncology medicines and diagnostics to satisfy the unique needs of the APAC market.
In 2018, APAC was responsible for 60% of all lung cancer cases and fatalities worldwide, as well as 75% of all stomach cancer cases and fatalities. 1 The high cancer burden in APAC will result in higher healthcare expenses. By 2022, oncology spending in Japan and other pharmerging countries like China and India is predicted to reach about $20 billion. 2 This is still a fraction of the US$140 billion that the US and the EU-5 are expected to spend. Because of availability and reimbursement constraints, emerging markets spend less on oncology drugs and diagnostics.
Asian patients, interestingly, have unique genetics in specific cancer forms. Patients with non-small celiac disease in East Asia,
Various diagnostic procedures, such as companion diagnostics (CDx), are used in precision oncology to establish if specific targeted treatments should be provided. CDx is often related to a specific drug within its approved label, unlike complementary diagnostics, which are associated with a class of pharmaceuticals and are not limited to specific uses in the labels. Despite the fact that numerous CDx types are utilised to test for corresponding targeted treatments in a variety of diseases, targeted cancer treatments account for over 90% of globally approved CDx tests.
Comments
Post a Comment